The limited doses of Ebola trial drugs must not be reserved for the well-off or well-connected, two medical ethics experts said on Thursday as two American doctors treated with an experimental serum were pronounced cured.
“Fair selection of participants is essential,” Ezekiel Emanuel of the University of Pennsylvania and Annette Rid of Kings College London wrote in The Lancet medical journal.
“Especially in a dire emergency such as this one, well-off and well-connected patients should not be further privileged.”
Continue..
